Book 01 / Healthspan & evidence
The Longevity Operating System
Mark A. Smith
A Practical, Evidence-Literate Guide to Healthspan, Measurement, and Self-Experimentation
Book 02 of the Longevity Evidence Series / Rapamycin & muscle
mTOR, Metabolism, and Muscle
Rapamycin, Exercise, and the Biology of Longevity Trade-offs
By Mark A. Smith
An examination of mTOR biology, rapamycin research, and the tension between growth, repair, and aging. Human trials, immune resilience, glucose tolerance, and muscle provide the tests of the theory—not a dosing protocol.
Download free PDFFree edition · 226 pages · 1.9 MB · No account needed
About this book
mTOR is not an on/off switch. This book explains how mTOR balances growth, repair, and aging, and follows rapamycin research from yeast, worms, and mice to the first serious human longevity conversations.
Human trials including PEARL and RAPA-EX are examined alongside immune resilience, glucose tolerance, and muscle — the real tests of the theory. Later chapters compare metformin, acarbose, SGLT2 inhibitors, and GLP-1 therapies, and ask what a definitive trial would look like. It is an evidence review, not a dosing protocol.
What’s inside
The biology
- mTOR Is Not an On/Off Button
- Growth, Repair, and Aging
- From Yeast and Worms to Mice
Human evidence
- What Rapamycin Is Actually Used For
- PEARL and the First Serious Longevity Conversations
- RAPA-EX—When Rapamycin Meets Exercise
- Immune Resilience, Infection, and Aging
Metabolism and muscle
- mTORC1, mTORC2, and Glucose Tolerance
- Muscle as the Test of the Theory
- Rapamycin Timing, Training, and Recovery
- Metformin and the Exercise Paradox
- Acarbose and SGLT2 Inhibitors
- GLP-1 Therapies, Retatrutide, and Lean Mass
The verdict
- The Evidence Matrix
- What Would a Definitive Trial Look Like?
- The Honest Conclusion
More from the series
Book 03 / Brain health & prevention
Outrunning Alzheimer’s
Mark A. Smith
What a Global Longevity Community Tested—and What the Evidence Now Says About Protecting Your Brain
Book 04 / GLP-1 & metabolic health
The Metabolic Frontier
Mark A. Smith
GLP-1 Medicines, Emerging Peptides, Gray-Market Risks, and the Science of Better Body Composition